Neeta Somaiah, MD

Peer-Reviewed Articles

1. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med 9(13):4593-4602, 2020. e-Pub 2020. PMID: 32374488.
2. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
3. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
4. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
5. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract 15(11):e925-e933, 2019. e-Pub 2019. PMID: 31268811.
6. Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res 25(19):5808-5817, 2019. e-Pub 2019. PMID: 31227504.
7. Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019. PMID: 31206726.
8. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
9. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
10. Keung Z, Somaiah N. Overview of liposarcomas and their genomic landscape. J Transl Genet Genom, 2019.
11. Wilkins A, Melcher A, Somaiah N. Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clin Oncol (R Coll Radiol) 30(10):605-608, 2018. e-Pub 2018. PMID: 30041845.
12. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget 9(69):33232-33243, 2018. e-Pub 2018. PMID: 30237864.
13. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
14. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9(28):19891-19899, 2018. e-Pub 2018. PMID: 29731991.
15. Beird HC, Wu CC, Ingram DR, Wang WL, Alimohamed A, Gumbs C, Little L, Song X, Feig BW, Roland CL, Zhang J, Benjamin RS, Hwu P, Lazar AJ, Futreal PA, Somaiah N. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud 4(2), 2018. e-Pub 2018. PMID: 29610390.
16. Zobniw CM, Trinh VA, Posey K, Somaiah N. Olaratumab in the management of advanced soft tissue sarcoma. J Oncol Pharm Pract((2)):442-448, 2018.
17. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23(1):62-70, 2018. e-Pub 2017. PMID: 28754721.
18. Goumard C, Marcal LP, Wang WL, Somaiah N, Okuno M, Roland CL, Tzeng CD, Chun YS, Feig BW, Vauthey JN, Conrad C. Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Ann Surg Oncol 25(1):107-116, 2018. e-Pub 2017. PMID: 29116489.
19. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2018. e-Pub 2017. PMID: 29308306.
20. Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology 7(5):e1420450, 2018. e-Pub 2018. PMID: 29721368.
21. Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123(23):4640-4647, 2017. e-Pub 2017. PMID: 28832986.
22. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
23. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
24. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease with Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
25. Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J. First-in-Human Treatment with a Dendritic Cell-Targeting Lentiviral Vector expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother 40(8):302-306, 2017. PMID: 28891906.
26. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
27. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. Mol Cancer Ther 16(9):1751-1764, 2017. e-Pub 2017. PMID: 28619757.
28. Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett Jun 23;403:216-223. doi:10.1016/j.canlet.2017.05.032:216-223, 2017. e-Pub 2017. PMID: 28652021.
29. de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG. High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol 10(4):546-554, 2017. e-Pub 2017. PMID: 28654818.
30. Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamidein Patients with Advanced Solid Organ Malignancies: HOG LUN 07-130. Am J Clin Oncol 40(4):329-335, 2017. PMID: 25503432.
31. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
32. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 8(24):39254-39267, 2017. PMID: 28424409.
33. Samuels BL, Chawla S, Somaiah N, Staddon A, Skubitz K, Milhem M, Kaiser P, Portnoy D, Priebat D, Walker MS, Stepanski EJ. Results of a Prospective Phase II Study of Pazopanib in Patients with Advanced Intermediate- or High-Grade Liposarcoma (CNCR-17-0785.R1). Cancer. Accepted, 2017.
34. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. Journal of Global Oncology DOI: 10.1200/JGO.2017.009993, 2017.
35. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma (ASPS). The Oncologist, 2017.
36. Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen D, Boonstra PA, Reyners AK, Gelderblom H, Steeghs N. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer 76:76-83, 2017. e-Pub 2017. PMID: 28284172.
37. Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol 35(12):1304-1311, 2017. e-Pub 2017. PMID: 28240971.
38. Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel T. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. J Comput Assist Tomogr 40(6):872-879(6):872-879, 2016. e-Pub 2016. PMID: 27454788.
39. Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 18(8):49, 2016. PMID: 27319943.
40. de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N. . Establishment and Characterization of a New Human Myxoid Liposarcoma Cell Line (DL-221) with the FUS-DDIT3 Translocation. Lab Invest Aug;96(8):885-94. doi: 10.1038/labinvest.2016.64(8):885-94, 2016. e-Pub 2016. PMID: 27270875.
41. Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes. Ann Surg Oncol 22(4):1068-72, 2015. e-Pub 2014. PMID: 25354575.
42. Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28(4):587-95, 2015. e-Pub 2014. PMID: 25412843.
43. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol S1-63(1 Suppl 1):S1-63, 2015. PMID: 25535693.
44. Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015:547460, 2015. e-Pub 2015. PMID: 25705114.
45. Tseng WW, Somaiah N, Engleman EG. Potential for immunotherapy in soft tissue sarcoma. Hum Vaccun Immunother 10(11):3117-24, 2014. PMID: 25412843.
46. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor (EGFR) mutations are exceptionally rare in thyroid transcription factor (ITTF-1)-negative adenocarcinomas of the lung. Oncoscience, 2014.
47. Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock RE. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. Ann Surg Oncol 21(7):2136-43, 2014. e-Pub 2014. PMID: 24705628.
48. Burgoyne AM, Somaiah N, Sicklick JK. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol 26(4):408-14, 2014. PMID: 24840526.
49. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
50. Al-Zaid T, Somaiah N, Lazar AJ. Targeted therapies for sarcomas: new roles for the pathologist. Histopathology 64(1):119-33, 2014. e-Pub 2013. PMID: 24117526.
51. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer 15(1):21-51, 2014. e-Pub 2013. PMID: 24377743.
52. Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR. Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control 21(1):57-62, 2014. PMID: 24357742.
53. Somaiah N. The Role of Combination Chemotherapy in GIST. GIST Cancer Journal, 2014.
54. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience 1(8):522-528, 2014. e-Pub 2014. PMID: 25594059.
55. Tseng WW, Somaiah N, Engleman EG. Potential for immunotherapy in soft tissue sarcoma. Hum Vaccin Immunother 10(11):3117-24, 2014. PMID: 25625925.
56. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) 5(2):529-49, 2013. e-Pub 2013. PMID: 24216990.
57. Somaiah N, Simon NG, Simon GR. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. J Thorac Oncol 7(16 Suppl 5):S342-68, 2012. PMID: 23160320.
58. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 69(4):977-82, 2012. e-Pub 2011. PMID: 22119758.
59. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?. Cancer Biol Ther 13(5):247-63, 2012. PMID: 22481432.
60. Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft tissue sarcoma: A review. Cancer Manag Res 2012:4:397-411, 2012. e-Pub 2012. PMID: 23226072.
61. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for lung cancer. J Thorac Oncol 6(11 Suppl 4):S1758-85, 2011. PMID: 22005529.
62. Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). J Thorac Oncol 6(1):227-32, 2011. PMID: 21178721.
63. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol 5(12 Suppl 6):S434-54, 2010. PMID: 21102235.
64. Aggarwal C, Somaiah N, Simon GR. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. J Natl Compr Canc Netw 8(7):822-32, 2010. PMID: 20679541.
65. Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU 3rd, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW; National Comprehensive Cancer Network Bone Cancer Panel. Bone Cancer. J Natl Compr Canc Netw 8(6):688-712, 2010. PMID: 20581300.
66. Somaiah N, Simon GR. Molecular targeted therapy in non-small cell lung cancer: an overview of available agents. J Thorac Oncol 4(11 Suppl 3):S1046-56, 2009. PMID: 19861914.
67. Banumathy G, Somaiah N, Zhang R, Tang Y, Hoffmann J, Andrake M, Ceulemans H, Schultz D, Marmorstein R, Adams PD. Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol 29(3):758-70, 2009. e-Pub 2008. PMID: 19029251.
68. Somaiah N, von Mehren M. New therapeutic approaches for advanced gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23(1):139-50, x, 2009. PMID: 19248977.
69. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, Adams PD. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27(7):2452-65, 2007. e-Pub 2007. PMID: 17242198.
70. Singhal R, Angmo N, Somaiah N, Majumdar H, Chaturvedi KU. A retrospective review of the histopathology and clinicopathologic correlates of appendices removed from patients of acute appendicitis. Minerva Chir 62(1):11-8, 2007. PMID: 17287689.
71. Al-Zaid T, Wang WL, Somaiah N, Lazar AJ. Molecular profiling of sarcomas: new vistas for precision medicine. Virchows Arch doi:10.1007/s00428-017-2174-3. e-Pub 2017. PMID: 28664413.
72. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. J Surg Oncol. e-Pub 2017. PMID: 29228466.
73. Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. e-Pub 2018. PMID: 29448300.
74. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Ann Surg Oncol. e-Pub 2018. PMID: 29520652.
75. Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Ann Surg Oncol. e-Pub 2020. PMID: 32409969.

Invited Articles

1. Somaiah, N. The Role of Combination Chemotherapy in GIST. GIST Cancer Journal, 2014.

Manuals, Teaching Aids, Other Teaching Publications

1. Somaiah N. VEGF - Targeting in Gastrointestinal Stromal Tumors, 2017.
2. Somaiah N. GIST Module. Clincal Care Options, 2015.

Other Articles

1. Zobniw CM, Trinh VA, Posey K, Somaiah N Olaratumab in the Management of Advanced Soft Tissue Sarcoma. J Oncol Pharm Pract 25(2):442-448, 2019. PMID: 30032714.
2. Sameer Rastogi, Aditi Aggarwal, Babita Kataria, Jyoti Bajpai and Neeta Somaiah Evidence Based Guidelines for medical oncologists regarding management of localized soft tissue sarcoma for developing countries. Sarcoma, 2017.
3. Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients: The MD Anderson Cancer Center experience. Scientific reports, 2017.
4. Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar A, Tseng W, Roland CL, Feig B, Pollock R, Conley AP, Benjamin RS, Patel SR, Somaiah N Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Accepted with revisions. Scientific reports, 2017.
5. Neeta Somaiah, Hannah Beird, Kenna Shaw, Juhee Song, Andrea Barbo, Wei-Lien Wang, Anthony Conley, Vinod Ravi, Ken Chen, Katrina Eterovic, Alexander J. F. Lazar, Patrick Hwu, Andrew Futreal, Funda Meric-Bernstam, David S. Hong Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS) reveals novel gene alterations. Oncotarget, 2017.
6. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N Early evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose doxorubicin given as a continuous infusion. Sarcoma 2017:7495914, 2017. PMID: 29081684.

Abstracts

1. Roland C, Keung E, Lazar A, Torres K, Wei-Lien W, Guadagnolo A, Bishop A, Lin H, Hunt K, Feig B, Bird J, Lewis V, Tawbi H, Ratan R, Patel S, Wargo J, Somaiah N. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). J Clin Oncol, ASCO Virtual Scientific Program 2020(38), 2020.
2. Somaiah N, Van Tine BA, Goodwin-Hill E, Milhem M. Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019.
3. von Mehren M, Litwin S, Vinod R, Schuetze S, Movva S, Agulnik M, Kraft A, Tetzlaff E, Somaiah N. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol, ASCO Annual Meeting 2019(37), 2019. e-Pub 2019.
4. Attia S, Pollack S, Van Tine BA, Chawla S, Druta M, Burgess M, Bohac G, Somaiah N. Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma. J Clin Oncol, ASCO Annual Meeting 2019(37), 2019.
5. D'Angelo S, Druta M, Liebner D, Schuetze S, Somaiah N, Van Tine B, Tap W, Pulham T, Chagin K, Norry E, Amado R. Pilot study of NY-ESO-1c259T cells in advanced myxoid/round cell liposarcoma. ASCO Annual Meeting 2018, 2018.
6. Neeta Somaiah, Sant P. Chawla, Matthew Stephen Block, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Mihaela Druta, Kamalesh Kumar Sankhala, Patrick Hwu, Sacha Gnjatic, Hailing Lu, Richard T. Kenney, Gerry C. Bohac, Seth Pollack. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). J Clin Oncol, ASCO Annual Meeting 2017, 2017.
7. Seth Pollack, Hailing Lu, Neeta Somaiah, Sant P. Chawla, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Matthew Stephen Block, Marissa Vignali, Julie Rytlewski, Erik Yusko, Frank J. Hsu, Gerry C. Bohac, Sacha Gnjatic. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. J Clin Oncol 35, 2017.
8. Sandra P. D'Angelo, Mihaela Druta, George D. Demetri, David A. Liebner, Scott Schuetze, Arun S. Singh, Neeta Somaiah, Brian Andrew Van Tine, Breelyn A. Wilky, Karen Chagin, Tim Pulham, Malini Iyengar, Elliot Norry, Arundathy N. Bartlett-Pandite, Rafael G. Amado. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743). J Clin Oncol 35, 2017.
9. John Andrew Livingston, Kristi Posey, Vivek Subbiah, Najat C. Daw, Neeta Somaiah, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Wei-Lien Wang, Alexander Lazar, Russell Broaddus, Funda Meric-Bernstam, Kenna Rael Shaw, Jason Roszik, Anthony Paul Conley. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. J Clin Oncol 35, 2017.
10. Filip Janku, Albiruni Ryan Abdul Razak, Michael S. Gordon, David Glenn Brooks, Daniel Lee Flynn, Michael Kaufman, Jama Pitman, Bryan Douglas Smith, Neeta Somaiah, John Frederick De Groot, Guo Chen, Julia Jennings, Samer Salah, Deb Westwood, Eric Gerstenberger, Oliver Rosen, Suzanne George. Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. J Clin Oncol 35, 2017.
11. Somaiah N, Chawla S, Block S, Morris J, Do K, Kim J, Druta M, Sankhala K, Hwu P, Gnjatic S, Lu H, Kenney R, Bohac G, Pollack S. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). J Clin Oncol, ASCO Annual Meeting 2017(35), 2017.
12. Schvartsman G, Wagner M, Barbo A, Lin H, Amini B, Trinh V, Wang WL, Patel SR, Benjamin RS, Somaiah N, The University of Texas MD Anderson Cancer Center. The Toxicity & Efficacy Profile of Regorafenib (RG) in Gastrointestinal Tumor (GIST) Patients Using An Alternate Dosing Regimen. Connective Tissue Oncology Society 2016, 2016.
13. Subbiah V, Anerson P, Kairemo K, Huh W, Ravi V, Daw N, Somaiah N, Benjamin B, Hong D, Macapinlac H, Ravizzini G, Rohren E. Alpha particle radium-223 dichloride (223RaCI2) therapy and personalized molecular imaging with bone scintigraphy, NAF-PET and FDG-PET in high risk osteosarcoma. Connective Tissue Oncology Society 2016, 2016.
14. Yu J, Wu C, Beird H, Bovee J, Lazar A, Somaiah N, Nielsen T. Myxiod Liposarcoma Fusion Protein FUS-DDIT3 Associates with PARP1, RNA Processing & DBHS Family Proteins (SFPS, NONO, PSPC1). Connective Tissue Oncology Society 2016, 2016.
15. Conley A, Wang WL, Ravi V, Roland C, Somaiah N, Hwu P, Yee C, Futreal A, Lazar A, Rosnik J. MAGEA3 Expression & Clinical Correlation In Sarcoma Subtypes. Connective Tissue Oncology Society 2016, 2016.
16. Conley A, Ravi V, Somaiah N, Patel SR, Benjamin RS, Zarzour MA, Ludwig JA, Araujo D, Huh W, Subbiah V. Safety, Toxicity, & Activity of Multi-Kinase VEGFR TKI Vandetanib Combined with MTOR Inhibitor Everolmus in an Advanced Sarcomas Cohort of a Phase I Study. Connective Tissue Oncology Society 2016, 2016.
17. Nathenson M, Ravi V, Lin H, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Conley A. The Role of Estrogen and Progesterone as Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016.
18. Stacchiotti S, Mir O, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Brhami M, Boye K, Hindi N, Paterczyk HK, Italiano A, Kobayashi E, Provenzo S, Kawai A. Pazopanib (P) and Trabectedin (T) in alveolar soft part sarcoma (ASPS). Connective Tissue Oncology Society 2016, 2016.
19. Nathenson MJ, Conley AP, Lin HY, Wang WL, Lazar A, Araujo D, Somaiah N, Zarzour MA, Ratan R, Patel SR, Benjamin RS, Ravi V. Prognostic Factors for Adenosarcoma of the Uterus. Connective Tissue Oncology Society 2016, 2016.
20. Neeta Somaiah, Matthew Stephen Block, Joseph W. Kim, Geoffrey Shapiro, Khanh Tu Do, Patrick Hwu, Joseph Paul Eder, Robin Lewis Jones, Sacha Gnjatic, Hailing Lu, Jan Ter Meulen, Frank J. Hsu, Seth Pollack; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Rochester, MN; Yale University-Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Fred Hutchinson Cancer Research Center, Seattle, WA; Icahn School of Medicine at Mount Sinai, New York, NY; Immune Design, Seattle, WA. Single-agent LV305 to induce anti-tumor immune & clinical responses in patients with advanced or metastatic sarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016. e-Pub 2016.
21. Michael Nathenson, Anthony Paul Conley, Ravin Ratan, Maria Alejandra Zarzour, Neeta Somaiah, Dejka M. Araujo, Shreyaskumar Patel, Robert S. Benjamin, Vinod Ravi. Efficacy of front-line chemotherapy for recurrent/metastatic Adenosarcoma of the uterus. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
22. Vivek Subbiah, Peter Meade Anderson, Kalevi Kairemo, Winston W. Huh, Vinod Ravi, Najat C. Daw, Neeta Somaiah, Robert S. Benjamin, David S. Hong, Gregory Ravizzini, Eric Rohren. Alpha particle radium-223 dichloride (223RaCI2) in high risk osteosarcoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
23. Anthony Paul Conley, Winston W. Huh, Jason Roszik, Douglas James Harrison, Andrea Anita Hayes-Jordan, Kathleen A Kehr, Ravin Ratan, Neeta Somaiah, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Joseph A. Ludwig, Wei-Lien Wang, Robert S. Benjamin, Shreyaskumar Patel. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
24. Roman Groisberg, David S. Hong, Filip Janku, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Paul Conley, Cynthia E. Herzog, Funda Meric-Bernstam, Vivek Subbiah. Clinical next-generation sequencing in sarcomas. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
25. Mrinal M. Gounder, Andrew J. Wagner, Neeta Somaiah, Richard F. Riedel, Gary K. Schwartz, Steven Attia, Albiruni R.A. Razak, Lee D. Cranmer, Scott H. Okuno, Mohammed M. Milhem, Cassandra Choe-Juliak, Sharon Shacham, Michael G. Kauffman, Sant P. Chawla; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke University Medical Center, Durham, NC; Columbia University Medical Center - New York Presbyterian Hospital, New York, NY; Mayo Clinic, Jacksonville, FL; Princess Margaret Hospital, Toronto, ON, Canada; University of Arizona Cancer Center, Tucson, AZ; Mayo Clinic, Rochester, MN; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; Karyopharm Therapeutics, Inc, Newton, MA; Director, Sarcoma Oncology Center, Santa Monica, CA. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, mulit-center, randomized blind study. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
26. Sheima Farag, Neeta Somaiah, Haesun Choi, Birthe Heeres, Wei-Lien Wang, Hester Van Boven, Petra M Nederlof, Robert S. Benjamin, Winette TA van der Graaf, Dirk J. Grunhagen, Pieter Boonstra, An K.L Reyners, Hans Gelderblom, Neeltje Steeghs. Clinical characteristics & treatment outcome in a large multicenter observational cohort of pdgfraexon 18 mutated. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
27. Vikas Dembla, Siqing Fu, Jennifer Wheler, David S. Hong, Filip Janku, Ralph Zinner, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Cynthia E. Herzog, Daniel D. Karp, Funda Meric-Bernstam, Vivek Subbiah. Outcomes of patients with advance sarcoma enrolled in clinical trials of pazopnib in combination of histone deacetylase. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
28. Mrinal M. Gounder, Todd Michael Bauer, Gary K. Schwartz, Tyler Masters, Richard D. Carvajal, Saeheum Song, Prasanna Kumar, Roohi Gajee, Oleg Zernovak, Michael M. Rosen, Jarema Peter Kochan, Shuquan Chen, David Michael Hyman, Sugun Gokmen, Funda Meric-Bernstam, Patricia LoRusso, Neeta Somaiah, Amy M. Weise, David S. Hong. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors & lymphoma. J Clin Oncol, ASCO Annual Meeting 2016(34), 2016.
29. Marieke A. de Graaff, MD, Shruti Malu, Alwine Kruisselbrink, Irma Guardiola, Patrick Hwu, Torsten O. Nielsen, Alexander J. Lazar, Neeta Somaiah, Judith Bovee. Identification of Novel Drugable Targets for the Treatment of Myxoid Liposarcomas. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
30. Daniela Katz, Heather Lin, Nikki Weaver, Johnathan Trent, Ariel Hammerman, PhD, Ilan Feldhamer, Dejka Araujo, Vinod Ravi, Anthony Conley, Wei-Lien Wang, Alexander Lazar, Shreyaskumar Patel, Robert Benjamin, Neeta Somaiah. Predicting Response to Second-Line Sunitinib (SU) Based on Duration of Treatment on Front-Line Imatinib (IM) Patients with Metastatic GIST. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
31. Vivek Subbiah, MD, Pete Anderson, Winston W. Huh, Vinod Ravi, Kenneth Hess, Najat C. Daw, Joanna G. Fernandez, Neeta Somaiah, Gregory Ravizzini, Kamalesh Sankhala, Sant P. Chawla, Cindy L. Schwartz, David S. Hong; Eric Rohren. Safety and Feasibility of Alpha Particle Radium-223 Dichloride Therapy in High Risk Osteosarcoma: A Phase 1 Dose Escalation Trial. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
32. Brian Samuels, MD, Sant P. Chawla, Neeta Somaiah, Arthur Staddon, Keith M. Skubitz, Kevin Mulvey, Mohammed Milhem, Pamela Kaiser, David Portnoy, Dennis Priebat, Mark Walker, Edward Stepanski. Phase II Study of Pazopanib in Patients with Advanced Intermediate of High-Grade Liposarcoma. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
33. N. Somaiah, E. Gilbert, A. P. Conley, A. M. Zarzour, S. Patel, R. S. Benjamin, P. Bhosle, H. Lin, K. Watson, B. Feig, K.E. Torres, C. Roland. PET/CT Imaging Might Be Superior to Percutaneous Biopsy in Identifying Dedifferentiation in Patients with Well-Differentiated (WDLS)/Dediffer. Connective Tissue Oncology Society (CTOS) Annual Meeting 2015, 2015.
34. Neeta Somaiah, Matthew Stephen Block, Joseph W. Kim, Geoffrey Shapiro, Patrick Hwu, Joseph Paul Eder, Robin Lewis Jones, Sacha Gnjatic, Hailing Lu, Frank James Hsu, Seth Pollack. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
35. Neeta Somaiah, Hannah Beird, Kenna Rael Shaw, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Keila E Torres, Davis Ingram, Christina Lynn Roland, Vivek Subbiah, Barry W. Feig, Alexander J. F. Lazar, Robert S. Benjamin, Shreyaskumar Patel, Patrick Hwu, Andrew Futreal, Funda Meric-Bernstam, David S. Hong. Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
36. Ranee Mehra, Aruna Turaka, Joshua E. Meyer, Brian L. Egleston, Tawee Tanvetyanon, Mary Colleen Pinder, Thomas J. Dilling, Charles C. Williams, Jhanelle Elaine Gray, Keisuke Shirai, R. Katherine Alpaugh, Debbie Riordan, Neeta Somaiah, Prashant C. Shah, Walter Joseph Scott, George R. Simon, Hossein Borghaei. Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
37. Andrew J. Wagner, Udai Banerji, Amit Mahipal, Neeta Somaiah, Heather Anne Hirsch, Craig Fancourt, Amy Levonas, Raymond Lam, Amy Meister, Ramon Karmel Kemp, Clayton Knox, Shelonitda Rose, David S. Hong. A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
38. Saroj Vadhan-Raj, Vinod Ravi, Xiao Zhou, Dejka M. Araujo, Neeta Somaiah, Anthony Paul Conley, Mary Daniel, Robert S. Benjamin, Shreyaskumar Patel, Ivan Spasojevic. Effects of fosaprepitan (Fosa) on ifosfamide (Ifex) metabolism in sarcoma patients (pts) receiving multi-day chemotherapy (CT) regimen on doxorubicin (Dox) and Ifex (AI): Randomized, cross-over study. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
39. Anthony Paul Conley, Robert L Satcher, Wei-Lien Wang, Alexander J. F. Lazar, Patricia S Fox, Patrick P. Lin, Bryan Moon, Justin E Bird, Dejka M. Araujo, Vinod Ravi, Neeta Somaiah, Shreyaskumar Patel, Robert S. Benjamin, Valerae O. Lewis. Clinical characteristics and treatment outcomes of clear cell chondrosarcomas: MD Anderson Cancer Center Series. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
40. Michael Wagner, Kenneth R. Hess, David S. Hong, Chad Tang, Aung Naing, Siqing Fu, Filip Janku, Sarina Anne Piha-Paul, Ralph Zinner, Jennifer J. Wheler, Apostolia Maria Tsimberidou, Shreyaskumar Patel, Neeta Somaiah, Vinod Ravi, Robert S. Benjamin, Funda Meric-Bernstam, Vivek Subbiah. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. J Clin Oncol, ASCO Annual Meeting 2015(33), 2015.
41. Conley AP, Wang W-L, Ravi V, Somaiah N, Subbiah V, Benjamin RS, Patel S. Clinical Outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
42. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Lazar AJ, Araujo D, Torres KE, Ali S, Miller VA, Benjamin RS. Targeted sequencing of leiomyosarcomas in the clinic: Potential for target identification. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
43. Conley AP, Somaiah N, Torres KE, Benjamin RS, Wang W-L, Hwu P, Patel S, Rohren E.. Predicting survival using FDG pet responses in patients with unclassified sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
44. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Araujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Meric-Bernstam F. Targeted-Based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
45. Livingston JA, Bugano D, Madewell J, Wang W-L, Conley AP, Ravi V, Araujo D, Tseng WW, Feig B, Torres KE, Benjamin RS, Somaiah, N. Assessing chemotherapy benefit in well-differentiated/De-differentiated liposarcoma. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
46. Somaiah N, Pollack SM, Wei-W, Araujo D, Amaria RN, Mittendon EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of IS-LV305, a third generation lentiviral vaccine in patients with ny-eso-1 positive malignancies. Connective Tissue Oncology Society (CTOS) Berlin, 2014.
47. Neeta Somaiah, Diogo Bugano Diniz Gomes, John E Madewell, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Joseph A. Ludwig, Robert S. Benjamin, Shreyaskumar Patel. Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience. American Society of Clinical Oncology (ASCO) Conference 2014, 2014.
48. Vivek Subbiah, Rishi Agarwal, Filip Janku, Apostolia Maria Tsimberidou, Shreyaskumar Patel, Robert S. Benjamin, Joseph A. Ludwig, Peter Meade Anderson, Dejka M. Araujo, Vinod Ravi, Anthony Paul Conley, Neeta Somaiah, Wei-Lien Wang, Aung Naing, Ralph Zinner, David S. Hong, Funda Meric-Bernstam. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
49. Saroj Vadhan-Raj, Xiao Zhou, Dejka M. Araujo, Neeta Somaiah, Anthony Paul Conley, Vinod Ravi, Mary Daniel, Robert S. Benjamin, Shreyaskumar Patel. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
50. Shadia Ibrahim Jalal, Nasser H. Hanna, Robin Zon, Gregory A. Masters, Hossein Borghaei, Karuna Koneru, Sunil S. Badve, Nagendra K Prasad, Neeta Somaiah, Jingwei Wu, Zhangsheng Yu, Lawrence H. Einhorn. Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: HOG LUN 07-130. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
51. Vinod Ravi, Naveen Ramesh, Madhavi Patnana, Anthony Paul Conley, Neeta Somaiah, Maria Alejandra Zarzour, Davis Ingram, Latasha Little, Alexei Protopopov, Alexander J. F. Lazar, Dejka M. Araujo, Keila E Torres, Shreyaskumar Patel, Jianhua Zhang, Siraj M. Ali, Vincent A. Miller, Philip J. Stephens, Robert S. Benjamin, Patrick Hwu, Andrew Futreal. Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. J Clin Oncol, ASCO Annual Meeting 2014(32:5s), 2014.
52. Somaiah N, Ingram D, Liu J, Bolshakov S, de Graaff M, Szuhai K, Aman P, Toress KE, Lev D, Nielsen T, Bovee J, Lazar AJ. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
53. Somaiah N, Raj S, Gupta R, Ravi V, Conley T, Araujo D, Benjamin R, Patel S, Banchs J, Vadhan-Raj S.. Low incidence of cardiotoxicity noted with high-dose doxorubicin (A) at 90mg/m2/cycle given as a continuous infusion. Connective Tissue Oncology Society (CTOS) 18th annual Meeting, 2013.
54. Tseng WW, Malu S, Zhang M, Somaiah N, Ingram D, Lev DC, Pollock R, Lizee G, Radvanyi L, Hwu P. A feasibility study and trial proposal of immune checkpoint blockage in well and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
55. Tseng WWW, Madewell J, Wang W, Somaiah N, Lazar A, Ghadimi M, Hoffman A, Pisters P, Lev D, Pollock R.. Analysis of locoregional disease patterns as a guide to the extent of resection in well differentiated and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
56. Ravi V, Ramesh N, Somaiah N, Leja M, Conley P, Ludwig J, Araujo D, Taylor S, Torres K, Wang W, Hunt K, Reardon M, Benjamin R, Patel S. Cardiac angiosarcoma: Clinical features and treatment outcomes. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
57. 12. Tseng WW, Malu S, Zhang M, Somaiah N, Ingram D, Lev DC, Pollock R, Lizee G, Radvanyi L, Hwu P. A feasibility study and trial proposal of immune checkpoint blockage in well and dedifferentiated retroperitoneal liposarcoma. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
58. 13. Tseng WWW, Madewell J, Wang W, Somaiah N, Lazar A, Ghadimi M, Hoffman A, Pisters P, Lev D, Pollock R. Analysis of locoregional disease patterns as a guide to the extent of resection in well differentiated and dedifferentiated retroperitoneal liposarcoma. . Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
59. 14. Ravi V, Ramesh N, Somaiah N, Leja M, Conley P, Ludwig J, Araujo D, Taylor S, Torrres K, Wang W, Hunt K, Reardon M, Benjamin R, Patel S. Cardiac angiosarcoma: Clinical features and treatment outcomes. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting, 2013.
60. 15. Somaiah N, Ingram D, Liu J, Bolshakov S, de Graaff M, Szuhai K, Aman P, Toress KE, Lev D, Nielsen T, Bovee J, Lazar AJ. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting (#1772991), 2013.
61. 16. Somaiah N, Raj S, Gupta R, Ravi V, Conley T, Araujo D, Benjamin R, Patel S, Banchs J, Vadhan-Raj S. Low incidence of cardiotoxicity noted with high-dose doxorubicin (A) at 90mg/m2/cycle given as a continuous infusion. Connective Tissue Oncology Society (CTOS) 18th Annual Meeting (#1764432), 2013.
62. Mehra R, Tuaka A, Meye J, inder-Schenck M, Shirai K, Somaiah N, Egleston B, Borghaei H, Simon G. Phase I study o vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer. NCCN 18th Annual Conference, 2012.
63. Held-Warmkessel J, Davey M, Litwin S, Lee J, Smith MR, Millenson M, Cohen AD, Somaiah N, Hudes GR, Plimack ER, Wong YN, Kim S, von Mehren M. Observational study of ifosamide (Ifos) neurotoxicity (N): The prospective use of a nursing assessment tool. J Clin Oncol, ASCO Annual Meeting 2012((#e19580)), 2012.
64. Tap WD, Van Tine BA, Elias AD, Livingston MB, Agulnik M, Cooney MM, Chmielowski B, Brenner AJ, Pennock GK, Somaiah N, Dang LH, Tian GG, Jones RL, Okuno SH, Loizos N, Nippgen J, Schwarts GK. A phase lb/ll study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRa monoclonal antibody olaratumab (IMC-3G3) in the treatment og advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting 2012, 2012.
65. Neeta Somaiah, George R. Simon; Medical University of South Carolina, Charleston, SC; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC. An analysis of target-specific patient resource utilization in NSCLC clinical trials. J Clin Oncol, ASCO Annual Meeting 2012, 2012.
66. 8. Tap WD, Van Tine BA, Elias AD, Livingston MB, Agulnik M, Cooney MM, Chmielowski B, Brenner AJ, Pennock GK, Somaiah N, Dang LH, Tian GG, Jones RL, Okuno SH, Loizos N, Nippgen J, Schwarts GK. A phase lb/ll study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRa monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). J Clin Oncol, ASCO Annual Meeting, 2012.
67. Neeta Somaiah,. An analysis of target-specific patient resource utilization in NSCLC clinical trials. J Clin Oncol, ASCO Annual Meeting 2012, 2012.
68. 10. Held-Warmkessel J, Davey M, Litwin S, Lee J, Smith MR, Millenson M, Cohen AD, Somaiah N, Hudes GR, Plimack ER, Wong YN, Kim S, von Mehren M. The prospective use of a nursing assessment tool. J Clin Oncol, ASCO Annual Meeting((#e19580)), 2012.
69. 11. Mehra R, Tuaka A, Meye J, inder-Schenck M, Shirai K, Somaiah N, Egleston B, Borghaei H, Simon G. Phase I study o vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer. NCCN 18th Annual Conference((#NCT01059552)), 2012.
70. Somaiah N, Garrett-Mayer E, Huang X, Wahlquist A, Danenberg K, Simon GR. Negative thyroid transcription factor (TTF-1) status predicts for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. J Clin Oncol, ASCO Annual Meeting 2011 (poster discussion)(29), 2011.
71. Jalal S, Bufill J, Guarino M, Somaiah N, Koneru K, McClean J, Nichols C, Wu J, Yu Z, Einhorn L. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. J Clin Oncol, ASCO Annual Meeting 2011, 2011.
72. Jalal S, Bufill J, Guarino M, Somaiah N, Koneru K, McClean J, Nichols C, Wu J, Yu Z, Einhorn L. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. J Clin Oncol, ASCO Annual Meeting, 2011.
73. 7. Somaiah N, Garrett-Mayer E, Huang X, Wahlquist A, Danenberg K, Simon GR. Negative thyroid transcription factor (TTF-1) status predicts for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. J Clin Oncol, ASCO Annual Meeting, 2011. e-Pub 2011.
74. Somaiah N, Al Saleem T, Watson JC, Scott WJ, Patchefsky A, von Mehren M. Comparing Intra-thoracic and Extra-thoracic Solitary Fibrous Tumors: a clinico-pathologic case series. 16th CTOS Annual Meeting, 2010.
75. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, Godwin AK, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib mesylate and sunitinib. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010.
76. Aggarwal C, Egleston B, Li L, Mehra R, Borghaei H, Somaiah N, Turaka A, lebenthal A, Scott W, Simon GR. Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010.
77. W.J. Scott, C. Aggarwal, A. Lebenthal, B. Egleston, H. Borghaei, R. Mehra, N. Somaiah, A. Turaka, G. R. Simon, Fox Chase Cancer Center, Philadelphia, PA. Influence of surgical interventions on survival in patients with stage III non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience. J Clin Oncol, ASCO Annual Meeting 2010(28:15s), 2010.
78. Somaiah N, Al Saleem T, Watson JC, Scott WJ, Patchefsky A, von Mehren M. Comparing Intra-thoracic and Extra-thoracic Solitary Fibrous Tumors: a clinico-pathologic case series. 16th CTOS Annual Meeting (#901100), 2010.
79. 3. Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, Godwin AK, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib mesylate and sunitinib. J Clin Oncol, ASCO Annual Meeting (28:15s) (#suppl; abstr 10090), 2010.
80. 4. W.J. Scott, C. Aggarwal, A. Lebenthal, B. Egleston, H. Borghaei, R. Mehra, N. Somaiah, A. Turaka, G. R. Simon. Influence of surgical interventions on survival in patients with stage IIIv non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting (28:15s) (#7067), 2010.
81. 5. Aggarwal C, Egleston B, Li L, Mehra R, Borghaei H, Somaiah N, Turaka A, lebenthal A, Scott W, Simon GR. Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience. J Clin Oncol, ASCO Annual Meeting, 2010.

Book Chapters

1. Parkes A, Somaiah N. In: Sarcomas: Evidence-Based Diagnosis and Management: Chapter 8, Leiomyosarcoma, 2020.
2. Somaiah N, Gupta R, Patel S. Chapter on Gastrointestinal Stromal Tumors. In: Textbook of GI Oncology, 2017.
3. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2016.
4. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2014.
5. Somaiah N, Patel S. Soft Tissue Sarcoma. In: Cancer Consult: Expertise for Clinical Practice. John Wiley and Sons, 2014.
6. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2013.
7. Somaiah N. Gastrointestinal Stromal Tumors: Clinical Care Options In Practice. In: Online book chapter, 2012.
8. Somaiah N, von Mehren M. The Role of Tyrosine Kinase Inhibitors in the Treatment of Gastrointestinal Stromal Tumors. In: Medscape, 2008.